<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="445">
  <stage>Registered</stage>
  <submitdate>7/09/2005</submitdate>
  <approvaldate>9/09/2005</approvaldate>
  <actrnumber>ACTRN12605000353695</actrnumber>
  <trial_identification>
    <studytitle>Tolerance 3</studytitle>
    <scientifictitle>The effects of repeated bronchoconstriction on response to "reliever" medication in asthma.</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Asthma</healthcondition>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Asthma</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Randomised, placebo-controlled, cross-over investigation. There will be two phases during which beta agonist will or will not be given on a regular basis. Each phase will last a month, with a 1-2 week washout period inbetween. At each visit, 2 bronchial challenges will be administered and either placebo, anti-cholinergic or beta-agonist relief will be given.</interventions>
    <comparator>Placebo</comparator>
    <control>Placebo</control>
    <interventioncode>None</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To confirm that the recovery to normal lung function, within 15 minutes, is impaired to a greater extent following repeated bronchoconstriction</outcome>
      <timepoint />
    </primaryOutcome>
    <primaryOutcome>
      <outcome>To distinguish if any impairment is specific for beta-agonist or also occurs with anti-cholinergic medication</outcome>
      <timepoint />
    </primaryOutcome>
    <primaryOutcome>
      <outcome>To assess if any of these effects are modified by regular bronchodilator</outcome>
      <timepoint />
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>None</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Asthma (according to the ATS), Non-smokers.</inclusivecriteria>
    <inclusiveminage>12</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>75</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Pregnancy, high dose ICS, history of life-threatening asthma, unable to tolerate ipratropium as a reliever inhaler, recent use of oral steroids, LRTI.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>The inhalers were blinded and labelled by a party not recording response and dispensed by the same party according to the randomisation sequence.</concealment>
    <sequence>Randomisation was by Latin Sqaure.</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>2/01/2004</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>12</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Charities/Societies/Foundations</primarysponsortype>
    <primarysponsorname>Otago Medical Research Foundation</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>New Zealand</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Otago Medical Research Foundation</fundingname>
      <fundingaddress />
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>Professor Robin Taylor</sponsorname>
      <sponsoraddress>Dunedin School of Medicine</sponsoraddress>
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Professor Robin Taylor</name>
      <address>Respiratory Research Unit
Department of Medical and Surgical Sciences
Dunedin Hospital
PO Box 913
Dunedin</address>
      <phone>+64 3 4740999 (Ext. 8785)</phone>
      <fax />
      <email>robin.taylor@stonebow.otago.ac.nz</email>
      <country>New Zealand</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Tim Sutherland</name>
      <address>Respiratory Research Unit
Department of Medical and Surgical Sciences
Dunedin Hospital
PO Box 913
Dunedin</address>
      <phone>+64 3 4740999 (Ext. 8785)</phone>
      <fax />
      <email>tim.sutherland@stonebow.otago.ac.nz</email>
      <country>New Zealand</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>